While artificial intelligence (AI) has been one of the hottest investing trends, GLP-1 weight loss drugs are a close second.

Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.

A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s ...

The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...

Eli Lilly said Wednesday it will invest $4.5 billion to build an advanced pharmaceutical drug manufacturing and development ...

We recently published an article titled, Jim Cramer is Talking About These 12 Stocks. In this article, we are going to take a ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Health care stocks underperformed the broader market in 2023, with many companies falling short of their profit targets, and ...

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer's disease, ALS and other brain ...